“…One of the main reasons for this, compared to successfully approved nanoDDS-based drugs, is the fact that, in general, carbon-based nanomaterials are considered to be one of the most dangerous nanomaterials with a high potential to penetrate cell walls due to their physicochemical properties, size and shape (e.g., risks of inflammatory reactions, pulmonary fibrosis and DNA damage) [ 74 , 110 , 111 , 112 , 113 ]. On the other hand, the functionalization of these nanomaterials leads to the suppression of toxic effects, which enables the successful integration of these nanomaterials into the biomedical field [ 26 , 104 , 105 , 114 , 115 ]. The aim of this paper is therefore to summarize the latest designed graphene-based (i.e., based on graphene, graphene quantum dots, graphene oxide, reduced graphene oxide) and carbon nanotube drug delivery systems mainly for anticancer therapy.…”